All In Biotech

Drug Trial Radar · NCT03972488

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 226 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

226

Actual

Start

Jan 8, 2020

Primary completion

Jul 20, 2023

Study completion Oct 29, 2027

Sponsor

Lead sponsor
Advanced Accelerator ApplicationsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of NETTER-2 was to determine if Lutathera in combination with long-acting octreotide prolongs progression free survival (PFS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients were eligible, as well as patients previously treated with SSAs in the absence of progression.

Conditions

  • Gastro-enteropancreatic Neuroendocrine Tumor

Interventions

  • LutatheraDrug

    Lutathera is a sterile radiopharmaceutical supplied as a ready-to-use solution for infusion containing 177Lu-DOTA0-Tyr3-octreotate as a drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time). Each Lutathera infusion continued for 30 min.

  • 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)Drug

    Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½" 19-gauge needles, and two alcohol wipes.

  • 2.5% Lys-Arg sterile amino acid solutionDrug

    Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.

  • High dose 60 mg octreotide long-acting repeatableDrug

    Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½" 19-gauge needles, and two alcohol wipes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) Per Central AssessmentTime frame: from randomization to the first line progression or death due to any cause, up to approx. 42 months

Locations

40 sites in 9 countries. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut

  • USF - H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • University of Iowa Hospitals and Clinics - Oncology

    Iowa City, Iowa

  • University of Kentucky UK Markey Cancer Center

    Lexington, Kentucky

  • Mayo Clinic - Oncology

    Rochester, Minnesota

  • MD Anderson Cancer Center

    Houston, Texas

  • London Health Sciences Centre, University of Western Ontario - Oncology

    London, Canada

  • Centre Hospitalier Universitaire de Quebec

    Québec, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Canada

  • BC Cancer Agency

    Vancouver, Canada

  • CHU Paris Nord-Val de Seine

    Clichy, France

  • Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot

    Lyon, France

  • Institut du Cancer de Montpellier - Oncology

    Montpellier, France

  • CHU-Hôtel Dieu Service de Médecine Nucléaire

    Nantes, France

  • Institut Gustave Roussy

    Villejuif, France

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitätsklinikum Essen - Klinik für Nuklearmedizin

    Essen, Germany

  • A.O.di Bologna Policl.S.Orsola

    Bologna, Italy

  • University of Genova - Oncology

    Genova, Italy

  • Istituto Oncologico Romagnolo

    Meldola, Italy

  • Fondazione Irccs Istituto Nazionale Tumori

    Milan, Italy

  • Ieo, Irccs

    Milan, Italy

  • IRCCS fondazione Pascale - Oncology

    Naples, Italy

  • Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology

    Reggio Emilia, Italy

  • Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology

    Roma, Italy

  • Erasmus Medisch Centrum

    Rotterdam, Netherlands

  • UMC Utrecht - Oncology

    Utrecht, Netherlands

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Asan Medical Center - Oncology

    Seoul, South Korea

  • Seoul National University Hospital - Department of Internal Medicine

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System - Medical Oncology

    Seoul, South Korea

  • Hospital Universitario Vall d'Hebrón

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom

  • Guys And St Thomas Hospital

    London, United Kingdom

  • Kings College Hospital - Oncology

    London, United Kingdom

  • Royal Free Hospital, London

    London, United Kingdom

  • Weston Park Hospital

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.